Clinical Trial: Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07815951) titled 'Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors' on Aug. 20.

Brief Summary: This study aims to evaluate the performance of a novel SPECT imaging agent, 111In-TJD-31, which targets placental alkaline phosphatase (ALPP). ALPP is a protein found on the surface of many malignant solid tumor cells but rarely present in healthy adult tissues. The purpose of this study is to assess the ability of 111In-TJD-31 to detect tumor lesions in patients with malignant solid tumors, as well as to evaluate its safety, biodistribution, pharmacokinetics, and radiation dosimetry.

The study will enroll 8 pa...